The Small Molecule Alpha-Synuclein Aggregator, FN075, Enhances Alpha-Synuclein Pathology in Subclinical AAV Rat Models

被引:5
|
作者
Kelly, Rachel [1 ]
Cairns, Andrew G. [2 ]
Aden, Jorgen [2 ]
Almqvist, Fredrik [2 ]
Bemelmans, Alexis-Pierre [3 ]
Brouillet, Emmanuel [3 ]
Patton, Tommy [1 ]
McKernan, Declan P. [1 ]
Dowd, Eilis [1 ]
机构
[1] Natl Univ Ireland Galway, Pharmacol & Therapeut & Galway Neurosci Ctr, Galway H91 W5P7, Ireland
[2] Umea Univ, Dept Chem, S-90187 Umea, Sweden
[3] Univ Paris Saclay, CNRS, CEA, Lab Malad Neurodegenerat,MIRCen, F-92265 Fontenay Aux Roses, France
基金
爱尔兰科学基金会; 瑞典研究理事会;
关键词
Parkinson's; alpha-synuclein; adeno-associated virus; AAV; phospho-alpha-synuclein; DOPAMINERGIC NEURON LOSS; PARKINSONS-DISEASE; NIGROSTRIATAL NEURODEGENERATION; MEDIATED OVEREXPRESSION; MESSENGER-RNA; CORRIDOR TASK; PHOSPHORYLATION; PESTICIDE; GENE;
D O I
10.3390/biom11111685
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Animal models of Parkinson's disease, in which the human alpha-synuclein transgene is overexpressed in the nigrostriatal pathway using viral vectors, are widely considered to be the most relevant models of the human condition. However, although highly valid, these models have major limitations related to reliability and variability, with many animals exhibiting pronounced alpha-synuclein expression failing to demonstrate nigrostriatal neurodegeneration or motor dysfunction. Therefore, the aim of this study was to determine if sequential intra-nigral administration of AAV-alpha-synuclein followed by the small alpha-synuclein aggregating molecule, FN075, would enhance or precipitate the associated alpha-synucleinopathy, nigrostriatal pathology and motor dysfunction in subclinical models. Rats were given unilateral intra-nigral injections of AAV-alpha-synuclein (either wild-type or A53T mutant) followed four weeks later by a unilateral intra-nigral injection of FN075, after which they underwent behavioral testing for lateralized motor functionality until they were sacrificed for immunohistological assessment at 20 weeks after AAV administration. In line with expectations, both of the AAV vectors induced widespread overexpression of human alpha-synuclein in the substantia nigra and striatum. Sequential administration of FN075 significantly enhanced the alpha-synuclein pathology with increased density and accumulation of the pathological form of the protein phosphorylated at serine 129 (pS129-alpha-synuclein). However, despite this enhanced alpha-synuclein pathology, FN075 did not precipitate nigrostriatal degeneration or motor dysfunction in these subclinical AAV models. In conclusion, FN075 holds significant promise as an approach to enhancing the alpha-synuclein pathology in viral overexpression models, but further studies are required to determine if alternative administration regimes for this molecule could improve the reliability and variability in these models.
引用
收藏
页数:18
相关论文
共 50 条
  • [31] Alpha-synuclein pathology in the olfactory pathways of patients with dementia
    Hubbard, P.
    Esiri, M.
    McShane, R.
    Nagy, Z.
    JOURNAL OF ANATOMY, 2006, 209 (04) : 563 - 563
  • [32] De novo design of alpha-synuclein small molecule PET tracers
    Korat, Spela
    Vugts, Danielle
    de Esch, Iwan
    Windhorst, Albert
    NUCLEAR MEDICINE AND BIOLOGY, 2022, 108 : S97 - S97
  • [33] Pathology and physiology of alpha-synuclein relevant to neurodegenerative diseases
    Kenji, UEDA
    JOURNAL OF NEUROCHEMISTRY, 2004, 88 : 6 - 6
  • [34] Tau and alpha-synuclein brainstem pathology in Alzheimer disease
    Attems, J
    Jellinger, KA
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2006, 32 (02) : 222 - 223
  • [35] Single-Molecule Characterisation of Alpha-Synuclein Oligomers
    Horrocks, Mathew H.
    Lee, Steven F.
    Gandhi, Sonia
    Iljina, Marija
    Tosatto, Laura
    Dobson, Christopher M.
    Klenerman, David
    BIOPHYSICAL JOURNAL, 2014, 106 (02) : 267A - 267A
  • [36] Spinal Cord Pathology in Alpha-Synuclein Transgenic Mice
    Mendritzki, Sonja
    Schmidt, Saskia
    Sczepan, Teresa
    Zhu, Xin-Ran
    Segelcke, Daniel
    Luebbert, Hermann
    PARKINSONS DISEASE, 2010, 2010
  • [37] Tau and alpha-synuclein brainstem pathology in Alzheimer disease
    Jellinger, KA
    Attems, J
    ACTA NEUROPATHOLOGICA, 2005, 110 (03) : 330 - 330
  • [38] Alpha-synuclein pathology in neurodegeneration and aging human brain
    Jellinger, KA
    ACTA NEUROPATHOLOGICA, 2004, 108 (04) : 370 - 371
  • [39] Alpha-Synuclein: Mechanisms of Release and Pathology Progression in Synucleinopathies
    Bras, Ines C.
    Outeiro, Tiago F.
    CELLS, 2021, 10 (02) : 1 - 19
  • [40] Is alpha-synuclein pathology a target for treatment of neurodegenerafive disorders?
    Windisch, M.
    Wolf, H. J.
    Hutter-Paier, B.
    Hofmeister, A.
    Wronski, R.
    CURRENT ALZHEIMER RESEARCH, 2007, 4 (04) : 446 - 457